Treatment of Sarcoidosis

doi:10.1016/j.ccm.2008.03.012

Clinics in Chest Medicine

Volume 29, Issue 3, September 2008, Pages 533-548

https://doi.org/10.1016/j.ccm.2008.03.012 Get rights and content

Not all patients who have sarcoidosis require treatment. For those who require treatment, the outcome of sarcoidosis can be considered conceptually in three broad, and at least partially overlapping, groupings: acute, chronic, and refractory. Although corticosteroids remain the initial drug for most patients who require therapy, several steroid-sparing alternatives have been found effective in treating many aspects of sarcoidosis. Methotrexate is most commonly used cytotoxic agent used for chronic disease, but azathioprine and leflunomide also have been shown to be useful. The tumor necrosis factor antibody infliximab has proved useful in treating refractory sarcoidosis. These various agents led to a treatment strategy for the various aspects of sarcoidosis.

Section snippets

Classification of sarcoidosis outcome

The outcome of sarcoidosis can be considered conceptually in three broad and at least partially overlapping groupings:

Acute disease—resolves within 2 to 5 years of time of diagnosis residual defects are fibrosis, not ongoing inflammation
Chronic disease—persists beyond 5 years after diagnosis
Refractory disease—chronic disease that worsens despite adequate systemic therapy

The authors have defined acute disease as disease that resolves within 5 years. Any residual abnormality is not caused by

Acute disease

During the first 2 to 5 years after diagnosis, an individual patient can be considered to have acute disease. There are some clinical features that predict chronic disease, but specificity is not total (see Table 1). It is appropriate, therefore, to not assume that chronicity is inevitable because of their presence but to await the passage of time. Fig. 2 demonstrates this approach to the patient who has disease of known duration less than 5 years. A significant percentage of these patients do

Individual agents

Several of the drugs used to treat sarcoidosis have been employed for all three categories of disease (acute, chronic, and refractory). Table 2 summarizes the individual drugs, their indications, their usual doses, common adverse effects, and monitoring recommendations. Most of these recommendations are not evidence-based, because there remains a paucity of randomized clinical trials to support the use of these drugs, and even less information regarding one dose versus another [47], [91], [92].

Summary

The use of systemic therapy in sarcoidosis requires a global approach to determine the total effect of drugs on disease symptomatology and time course. Steroid-sparing treatments have become standard for chronic disease. In some cases, refractory disease may require drugs other than corticosteroids. Knowledge of the relative risk and benefits of these agents has to be considered in the care of patients who have sarcoidosis.

References (155)

R.P. Baughman et al.
Sarcoidosis
Lancet
(2003)
R. Sulica et al.
Distinctive clinical, radiographic, and functional characteristics of patients with sarcoidosis-related pulmonary hypertension
Chest
(2005)
J. Mana et al.
Erythema nodosum
Clin Dermatol
(2007)
O.P. Sharma
Sarcoidosis: a historical perspective
Clin Dermatol
(2007)
J. Mana et al.
Lofgren's syndrome revisited: a study of 186 patients
Am J Med
(1999)
R.P. Baughman et al.
Thalidomide for chronic sarcoidosis
Chest
(2002)
S.M. Chan et al.
Anterior and intermediate uveitis cases referred to a tertiary centre in Alberta
Can J Ophthalmol
(2007)
R.P. Baughman et al.
Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial
Chest
(2005)
J.E. Gottlieb et al.
Outcome in sarcoidosis. The relationship of relapse to corticosteroid therapy
Chest
(1997)
A. Pietinalho et al.
Oral prednisolone followed by inhaled budesonide in newly diagnosed pulmonary sarcoidosis: a double-blind, placebo-controlled, multicenter study
Chest
(1999)

A. Pietinalho et al.

Early treatment of stage II sarcoidosis improves 5-year pulmonary function

Chest

(2002)

R.P. Baughman et al.

Evidence-based therapy for cutaneous sarcoidosis

Clin Dermatol

(2007)

M.A. Judson

An approach to the treatment of pulmonary sarcoidosis with corticosteroids: the six phases of treatment

Chest

(1999)

A. Gedalia et al.

Low-dose methotrexate therapy for childhood sarcoidosis

J Pediatr

(1997)

E. Jones et al.

Hydroxychloroquine is effective therapy for control of cutaneous sarcoidal granulomas

J Am Acad Dermatol

(1990)

E. Goleva et al.

Airway remodeling and lack of bronchodilator response in steroid-resistant asthma

J Allergy Clin Immunol

(2007)

Y.T. Nguyen et al.

Treatment of cutaneous sarcoidosis with thalidomide

J Am Acad Dermatol

(2004)

J.D. Doty et al.